{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:56:21Z","timestamp":1773057381343,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T00:00:00Z","timestamp":1480636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shire Human Genetic Therapies, Inc"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.10.014","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T23:07:01Z","timestamp":1477004821000},"page":"218-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey"],"prefix":"10.1016","volume":"68","author":[{"given":"P.","family":"Deegan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Fernandez-Sasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Panahloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.10.014_bb0005","series-title":"Williams Hematology","article-title":"Gaucher disease and related lysosomal storage diseases","author":"Zimran","year":"2016"},{"key":"10.1016\/j.bcmd.2016.10.014_bb0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","article-title":"Individualization of long-term enzyme replacement therapy for Gaucher disease","volume":"7","author":"Andersson","year":"2005","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0025","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials","volume":"90","author":"Hughes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0030","first-page":"81","article-title":"Imiglucerase in the treatment of Gaucher disease: a history and perspective","volume":"6","author":"Deegan","year":"2012","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0040","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.10.014_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","article-title":"Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease","volume":"44","author":"Hollak","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0050","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bcmd.2010.10.015","article-title":"Early access experience with VPRIV\u00ae: recommendations for 'core data' collection","volume":"47","author":"Hughes","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0055","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0060","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.10.014_bb0065","author":"European Medicines Agency"},{"key":"10.1016\/j.bcmd.2016.10.014_bb0070","author":"Actelion Pharmaceuticals US Inc."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0075","author":"Genzyme Corporation"},{"key":"10.1016\/j.bcmd.2016.10.014_bb0080","author":"European Medicines Agency"},{"key":"10.1016\/j.bcmd.2016.10.014_bb0085","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","article-title":"Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease","volume":"91","author":"Elstein","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.bcmd.2016.10.014_bb0100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.21362","article-title":"The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients","volume":"84","author":"Taddei","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0105","first-page":"855","article-title":"High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews","volume":"49","author":"Zimran","year":"1991","journal-title":"Am. J. Hum. Genet."},{"issue":"Suppl 1","key":"10.1016\/j.bcmd.2016.10.014_bb0110","first-page":"S12","article-title":"Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher Registry","volume":"90","author":"Grabowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ajh.21369","article-title":"Enzyme replacement therapy for mild patients with Gaucher disease","volume":"84","author":"Zimran","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0120","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","article-title":"How I treat Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.10.014_bb0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(94)90042-6","article-title":"Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment","volume":"97","author":"Zimran","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.014_bb0130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genet. Med."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:44Z","timestamp":1761050084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616302133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":26,"alternative-id":["S1079979616302133"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.014","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Shire Human Genetic Therapies, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}